naion with semaglutide use in patients diabetes was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) at 2, 3, and 4 years. https://ja.ma/4iZkMeV Study Links Semaglutide to Increased

[PMID 38958939, PMID 39976940, PMID 42060879] CONTRAINDICATIONS A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy PRECAUTIONS Kidney disease No dose adjustment is necessary for any degree of renal impairment Liver disease No dose adjustment is necessary for any degree of hepatic impairment Stomach disorders Wegovy slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like Wegovy, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures

To learn more about safety managing your pain, check out the official NHS resources on paracetamol and ibuprofen

The default works for most peptides but not all

Consult a licensed physician before making any decision about GLP-1 therapy

The litigation continued to expand as the parties moved into the next phase of expert challenges, with the court considering evidence on whether GLP-1 medications can cause gastroparesis and other serious gastrointestinal injuries